Skip to main content

A Study of Venetoclax and AMG 176 in Patients With Relapsed / Refractory Hematologic Malignancies

Trial Status: Temporarily Closed to Accrual

This dose-escalation study evaluating the safety, pharmacokinetics and preliminary efficacy of venetoclax in combination with AMG 176 in participants with relapsed or refractory acute myeloid leukemia (AML) and participants with Non-Hodgkin's lymphoma (NHL) / diffuse large B-cell lymphoma (DLBCL). This study will include a dose escalation phase to identify the maximum tolerated dose / recommended phase 2 dose (MTD / RPTD) of venetoclax plus AMG 176 as well as a dose expansion phase to confirm safety, explore efficacy, and confirm the suitability of the preliminary RPTD.

Inclusion Criteria

  • Adequate kidney, liver and hematology values as described in the protocol.
  • Diagnosis of relapsed or refractory (R/R) acute myeloid leukemia (AML) or R/R Non-Hodgkin's lymphoma (NHL)/diffuse large B-cell lymphoma (DLBCL) confirmed by the World Health Organization (WHO) criteria, as appropriate.
  • Meets the following disease activity criteria:
  • AML: must have received at least 1 prior therapy for AML and be ineligible for cytotoxic therapy and allogeneic stem cell transplant.
  • NHL/DLBCL: measurable disease with a bidimensional lesion measuring at least 1.5 cm; received at least 1 prior therapy for NHL with no curative treatment option as determined by the investigator and be ineligible for a stem cell transplant.

Exclusion Criteria

  • History of clinically significant medical condition that, in the opinion of the investigator, would adversely affect participation in this study.
  • History of of any malignancy within the last 6 months except for those specified in this protocol and low-grade malignancies not requiring active treatment such as non-melanoma skin cancer, cervical intraepithelial neoplasia, or prostate cancer in situ.
  • Prior allogeneic stem cell transplant or autologous stem cell transplant within 100 days of study drug administration and no signs or symptoms of acute or chronic graft-versus-host disease.
  • Previous enrollment in a randomized trial including either venetoclax or AMG 176.
  • Known active or chronic pancreatitis; severe chronic obstructive pulmonary disease with hypoxemia; central nervous system manifestations of malignancy.
  • Active, uncontrolled infection.


City of Hope Comprehensive Cancer Center
Status: ACTIVE


Iowa City
University of Iowa / Holden Comprehensive Cancer Center


Kansas City
University of Kansas Cancer Center
Contact: Adam Hisham AlDouri
Phone: 913-945-7547


Saint Louis
Siteman Cancer Center at Washington University

North Carolina

Chapel Hill
UNC Lineberger Comprehensive Cancer Center


University of Pittsburgh Cancer Institute (UPCI)
Status: ACTIVE

Trial Phase Phase I

Trial Type Treatment

Lead Organization

  • Primary ID M16-785
  • Secondary IDs NCI-2019-00764, 2018-003314-41
  • ID NCT03797261